Arbutus to Participate at H.C. Wainwright Global Life Sciences Conference
March 02 2021 - 8:00AM
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage
biopharmaceutical company primarily focused on developing a cure
for people with chronic hepatitis B virus (HBV) infection, as well
as therapies to treat coronaviruses (including COVID-19), today
announced that William Collier, Arbutus’ President and Chief
Executive Officer, will present at the H.C. Wainwright Global Life
Sciences Conference held virtually from March 9-10, 2021.
A webcast of the virtual presentation will be
available starting at 7:00 am (EST) on March 9, 2021, and can be
accessed through the Investors section of Arbutus' website at
www.arbutusbio.com or directly at Webcast. An archived
replay of the webcast will be available on the Company’s website
after the conference.
About Arbutus
Arbutus Biopharma Corporation is a publicly
traded (Nasdaq: ABUS) biopharmaceutical company primarily dedicated
to discovering, developing and commercializing a cure for people
with chronic hepatitis B virus (HBV) infection. The Company is
advancing multiple drug product candidates that may be combined
into a potentially curative regimen for chronic HBV infection.
Arbutus has also initiated a drug discovery and development effort
for treating coronaviruses (including COVID-19). For more
information, visit www.arbutusbio.com.
Contact Information
Investors and Media
William H. CollierPresident and CEO Phone: 267-469-0914Email:
ir@arbutusbio.comPam MurphyInvestor Relations ConsultantPhone:
267-469-0914Email: ir@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Apr 2023 to Apr 2024